Standalone 37% growth masked by Huron's ₹100-crore export gridlock

The headline is deceptive. Revenue growth looks solid at 24%, but consolidated profit actually fell 20% — the opposite of what you'd expect from expanding sales. This gap tells the whole story of Q1.

Standalone India is doing exactly what management promised: ₹509 crore revenue (+37% YoY), 27.2% EBITDA margin, PAT up 21% to ₹88 crore. But consolidated India-plus-Huron tells a different story. Huron, the French CNC subsidiary, generated only ₹35 crore in Q1 vs ₹70 crore a year ago. That ₹35 crore revenue miss carried a ₹20–22 crore margin hit. The reason: export licensing delays and an accounting method change mid-year.

Huron used percentage-of-completion accounting to recognize revenue on large defence and aerospace machines as they're built over 6–12 months. But in Q4 FY26, auditors demanded a shift: no revenue until end-user certificates arrive. Why? Export licenses from the EU and German defence ministry are taking far longer than historical norms — 7–8 machines (~₹35 crore per quarter) are stuck awaiting certifications for Chinese and Turkish customers, caught in US-China geopolitical tensions and EU defence scrutiny. The method switch meant Q4 FY26 saw ₹67 crore revenue reversed, and Q1 FY27 just saw ₹35 crore deferred. Total unrecognized backlog: ~₹100 crore. When licenses clear, that revenue will lump into one quarter — optics victory, but no new cash gain.

If Huron's ₹20–22 crore margin hit fully explained the consolidated profit slide, that would be the end of the story. But it doesn't. Consolidated EBITDA was 21.4%, vs. a 25% guidance — a 360 basis-point miss (or 150 bps adjusted for forex). Management blamed Huron entirely, but the math doesn't hold: PAT fell 20% YoY despite 24% revenue growth. That's negative operating leverage of 400+ basis points. In other words, costs are rising faster than revenue — and not just from Huron. Interest expense is up (capex financing ₹450 crore for the new facility), staffing costs are up, and facility ramp absorption hasn't been itemized. Analyst push-back on the call hinted at this; the CFO didn't challenge the broader cost narrative, only reaffirmed Huron as the primary culprit.

Huron export delays went public. Prior calls made no mention of licensing bottlenecks; this call revealed 7–8 machines (~₹35 crore per quarter) in customs hold awaiting EU/German defence ministry certifications. The accounting method switched from POCM to delivery-basis mid-year — auditor-driven conservatism re. geopolitical risk. Order book raised to ₹4,848 crore from ₹4,585 crore guidance (+₹263 crore, +5.7%), but this came with no upgrade to revenue or margin guidance. Capacity expansion remains on track (99%) for Sep 2026, expanding from 6,000 to 10,000 machines/year. But the new facility's ramp-up costs — depreciation, staffing, interest on ₹450 crore capex — are being absorbed as a drag on margins, not detailed as discrete line items.

The stock popped on the result announcement (day 1 +2.17%, held to day 5 +5.75%). That's a tentative thumbs-up, not a conviction buy. More telling: the stock is -21.69% from its all-time high of ₹1,055.9, now at ₹826.9 — near its 50-day and 200-day moving averages, suggesting consolidation. FII ownership has been trimming: down 2.65 percentage points QoQ to just 6.29%. That's smart-money skepticism on the margin story. RSI is 54.7 (neutral), not overbought. The market accepted the result but is not excited — it's waiting for proof that Sep's facility ramp and Huron's license batch clearance will restore margin to guidance.